

SIMICA ID

Project title
**Therapeutic site-Selective
protein-ModifiCAtion chemistries**

Project acronym
SIMICA

Project reference
852985

Project coordinator
Bruno Oliveira (iMM)

Funding scheme:
**H2020-WIDESPREAD-2018-2020 (Spreading
Excellence and Widening Participation -
Twinning)**

Total investment
EUR 800 000

Start date
1st October 2019

End date
30th September 2022

Consortium
• iMM – Portugal
• ALLC – Austria
• LUMC – Netherlands
• PERC – Netherlands
• UCAM – United Kingdom



THERAPEUTIC SITE-SELECTIVE PROTEIN-MODIFICATION CHEMISTRIES

Twinning is an action from “Spreading Excellence and Widening Participation” - Horizon 2020 programme and its main objective is to address networking gaps and deficiencies between research institutions of the low performing Member States and internationally-leading counterparts at EU level.

Consortium



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 852985

Wish to contact us?

Instituto de Medicina Molecular João Lobo Antunes
Faculdade de Medicina da Universidade de Lisboa

- Av. Professor Egas Moniz; 1649-028 Lisboa - Portugal
- alexandrrosa@medicina.ulisboa.pt
- www.simicatwinning.eu
- [linkedin.com/in/simica-twinning-project-at-imm/](https://www.linkedin.com/in/simica-twinning-project-at-imm/)
- twitter.com/@SIMICA_IMM

What is SIMICA?

SIMICA is a project funded by the European Union's Horizon 2020 that intends to place the Instituto de Medicina Molecular João Lobo Antunes (iMM), in Lisbon, within the core of a European network of laboratories that seeks to produce cutting-edge research in the field of antibody-drug conjugates (ADCs).

The SIMICA Network will be critical for strengthening the science and technology capacity of iMM in the study of protein-drug conjugates as well as to leverage research excellence and create value. This will be achieved through molecular and chemical innovation with a beneficial outcome for the entire research and development community at iMM.

Main goals



Place iMM at the forefront of Science and processes in Europe



Contribute to increased science awareness among the general public



Ignite an ambitious research community



Leverage iMM's research excellence and impact across its different research areas



Increase participation in international collaborative projects



Scientific and innovative boost to the region and the country



Increase the entrepreneurial and risk-taking spirit among iMM's community



Better integration of iMM in regional, national and European business community

Activities

- Staff exchanges
- Summer schools
- Mentorship programme
- Consortium meetings
- Workshops
- Dissemination and outreach
- Expert visits

The SIMICA consortium



iMM | Instituto de Medicina Molecular João Lobo Antunes - Portugal

The iMM is a non-profit private research institute affiliated with the University of Lisbon Medical School and located in the campus of the Santa Maria University Hospital. iMM has established itself as a leading national biomedical institute fostering the highest quality basic, clinical and translational biomedical research.

allcyte:

ALLC | Allcyte - Austria

ALLC is a Austrian biotech company which was founded in 2010 by Dr Krall. The expertise of ALLC, specifically Dr Krall, is in the field of biomarker discovery and development, with early origins working on epigenetic assays. ALLC will assist iMM to produce a companion diagnostic assay for ADCs.



LUMC | Leiden University Medical Center - Netherlands

Leiden University Medical Centre is a long-established university medical centre focusing on top clinical and specialized care. This is backed up by top tier research groups including imaging and tumour immunology for which it has world renowned status. It has four large public interest missions: research, education, public health and valorisation of scientific research via technology transfer and industrial partnerships.



PERC | Percuros B.V. - Netherlands

PERC, a Dutch biotech-chemistry company, was founded by Alan Chan in 2006 based on blood biomarkers. A KGI spin-off, Zuyder Inc., was subsequently incorporated into PERC. The Company graduated towards developing biomarker assays for immunotherapy and oncology and to this day it specialises in designing both in vitro and in vivo assays for clients.



UCAM | University of Cambridge - United Kingdom

The UCAM is one of the most renowned research/ higher education institutes and is frequently ranked amongst the top 5 in international academic rankings such as ARWU and Shanghai Ranking. It has a long-standing history of academic and scientific excellence backed up with rich culture, learning, research and creativity. The Chemistry Department is consistently ranked in the top three Chemistry Departments worldwide.